Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently. We comprehensively analyzed the clinical effects of galantamine or cilostazol monotherapy to the add-on combination therapy on three major factors of dementia, such as cognitive, affective and activities of daily living functions in AD patients with asymptomatic lacunar infarction. Methods: We divided 101AD patients with asymptomatic lacunar infarction into two subgroups: groupA (n=61, first treated with galantamine and then cilostazol added) and groupB (n=40, first treated with cilostazol and galantamine added). We compared the clinical effects before and after combination therapy of galantamine and cilostazol (i.e. 3months [M] before (-3M), baseline (0M), 3 and 6M after the add-on combination). Results: Galantamine monotherapy increased cognitive Hasegawa dementia score-revised scores, which were further improved with add-on cilostazol. Cilostazol monotherapy also increased the cognitive tests, which were further improved with add-on galantamine. Add-on cilostazol significantly improved Geriatric Depression Scale and Abe's behavioral and psychological symptoms of dementia scores after galantamine monotherapy. Cilostazol monotherapy also significantly improved Geriatric Depression Scale scores, with further improvements in Geriatric Depression Scale, apathy scores and Abe's behavioral and psychological symptoms of dementia scores by add-on galantamine. Activities of daily living scores continuously improved with galantamine monotherapy and add-on cilostazol. Conclusions: The present study provides a clinical possibility that galantamine or cilostazol monotherapy and the combination therapy maintained or even improved cognitive, affective, and activities of daily living functions in AD with asymptomatic lacunar infarction.

Original languageEnglish
JournalGeriatrics and Gerontology International
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Galantamine
Lacunar Stroke
dementia
Alzheimer Disease
geriatrics
Dementia
Activities of Daily Living
Geriatrics
Therapeutics
Behavioral Symptoms
Depression
apathy
coexistence
cilostazol
Psychology
pathology
Cerebrovascular Disorders
Apathy
Disease

Keywords

  • Alzheimer's disease
  • Asymptomatic lacunar infarction
  • Cilostazol
  • Cognitive/affective functions
  • Galantamine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Gerontology
  • Health(social science)

Cite this

@article{bfb0b244cb3140a9a3e5111542a4661c,
title = "Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction",
abstract = "Aim: The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently. We comprehensively analyzed the clinical effects of galantamine or cilostazol monotherapy to the add-on combination therapy on three major factors of dementia, such as cognitive, affective and activities of daily living functions in AD patients with asymptomatic lacunar infarction. Methods: We divided 101AD patients with asymptomatic lacunar infarction into two subgroups: groupA (n=61, first treated with galantamine and then cilostazol added) and groupB (n=40, first treated with cilostazol and galantamine added). We compared the clinical effects before and after combination therapy of galantamine and cilostazol (i.e. 3months [M] before (-3M), baseline (0M), 3 and 6M after the add-on combination). Results: Galantamine monotherapy increased cognitive Hasegawa dementia score-revised scores, which were further improved with add-on cilostazol. Cilostazol monotherapy also increased the cognitive tests, which were further improved with add-on galantamine. Add-on cilostazol significantly improved Geriatric Depression Scale and Abe's behavioral and psychological symptoms of dementia scores after galantamine monotherapy. Cilostazol monotherapy also significantly improved Geriatric Depression Scale scores, with further improvements in Geriatric Depression Scale, apathy scores and Abe's behavioral and psychological symptoms of dementia scores by add-on galantamine. Activities of daily living scores continuously improved with galantamine monotherapy and add-on cilostazol. Conclusions: The present study provides a clinical possibility that galantamine or cilostazol monotherapy and the combination therapy maintained or even improved cognitive, affective, and activities of daily living functions in AD with asymptomatic lacunar infarction.",
keywords = "Alzheimer's disease, Asymptomatic lacunar infarction, Cilostazol, Cognitive/affective functions, Galantamine",
author = "Nozomi Hishikawa and Yusuke Fukui and Kota Sato and Yasuyuki Ohta and Toru Yamashita and Koji Abe",
year = "2016",
doi = "10.1111/ggi.12870",
language = "English",
journal = "Geriatrics and Gerontology International",
issn = "1447-0594",
publisher = "Japan Geriatrics Society",

}

TY - JOUR

T1 - Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction

AU - Hishikawa, Nozomi

AU - Fukui, Yusuke

AU - Sato, Kota

AU - Ohta, Yasuyuki

AU - Yamashita, Toru

AU - Abe, Koji

PY - 2016

Y1 - 2016

N2 - Aim: The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently. We comprehensively analyzed the clinical effects of galantamine or cilostazol monotherapy to the add-on combination therapy on three major factors of dementia, such as cognitive, affective and activities of daily living functions in AD patients with asymptomatic lacunar infarction. Methods: We divided 101AD patients with asymptomatic lacunar infarction into two subgroups: groupA (n=61, first treated with galantamine and then cilostazol added) and groupB (n=40, first treated with cilostazol and galantamine added). We compared the clinical effects before and after combination therapy of galantamine and cilostazol (i.e. 3months [M] before (-3M), baseline (0M), 3 and 6M after the add-on combination). Results: Galantamine monotherapy increased cognitive Hasegawa dementia score-revised scores, which were further improved with add-on cilostazol. Cilostazol monotherapy also increased the cognitive tests, which were further improved with add-on galantamine. Add-on cilostazol significantly improved Geriatric Depression Scale and Abe's behavioral and psychological symptoms of dementia scores after galantamine monotherapy. Cilostazol monotherapy also significantly improved Geriatric Depression Scale scores, with further improvements in Geriatric Depression Scale, apathy scores and Abe's behavioral and psychological symptoms of dementia scores by add-on galantamine. Activities of daily living scores continuously improved with galantamine monotherapy and add-on cilostazol. Conclusions: The present study provides a clinical possibility that galantamine or cilostazol monotherapy and the combination therapy maintained or even improved cognitive, affective, and activities of daily living functions in AD with asymptomatic lacunar infarction.

AB - Aim: The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently. We comprehensively analyzed the clinical effects of galantamine or cilostazol monotherapy to the add-on combination therapy on three major factors of dementia, such as cognitive, affective and activities of daily living functions in AD patients with asymptomatic lacunar infarction. Methods: We divided 101AD patients with asymptomatic lacunar infarction into two subgroups: groupA (n=61, first treated with galantamine and then cilostazol added) and groupB (n=40, first treated with cilostazol and galantamine added). We compared the clinical effects before and after combination therapy of galantamine and cilostazol (i.e. 3months [M] before (-3M), baseline (0M), 3 and 6M after the add-on combination). Results: Galantamine monotherapy increased cognitive Hasegawa dementia score-revised scores, which were further improved with add-on cilostazol. Cilostazol monotherapy also increased the cognitive tests, which were further improved with add-on galantamine. Add-on cilostazol significantly improved Geriatric Depression Scale and Abe's behavioral and psychological symptoms of dementia scores after galantamine monotherapy. Cilostazol monotherapy also significantly improved Geriatric Depression Scale scores, with further improvements in Geriatric Depression Scale, apathy scores and Abe's behavioral and psychological symptoms of dementia scores by add-on galantamine. Activities of daily living scores continuously improved with galantamine monotherapy and add-on cilostazol. Conclusions: The present study provides a clinical possibility that galantamine or cilostazol monotherapy and the combination therapy maintained or even improved cognitive, affective, and activities of daily living functions in AD with asymptomatic lacunar infarction.

KW - Alzheimer's disease

KW - Asymptomatic lacunar infarction

KW - Cilostazol

KW - Cognitive/affective functions

KW - Galantamine

UR - http://www.scopus.com/inward/record.url?scp=84984684802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984684802&partnerID=8YFLogxK

U2 - 10.1111/ggi.12870

DO - 10.1111/ggi.12870

M3 - Article

C2 - 27578455

AN - SCOPUS:84984684802

JO - Geriatrics and Gerontology International

JF - Geriatrics and Gerontology International

SN - 1447-0594

ER -